Wellreme Wart Removal

Description

The product is identified by SPL code 34089-3. It is presented as a white to off-white, round, biconvex tablet, which is debossed with "XYZ" on one side and "123" on the opposite side. Each tablet contains 500 mg of the active ingredient. The formulation includes inactive ingredients such as lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, and magnesium stearate.

Uses and Indications

This drug is indicated for the removal of common warts, characterized by a rough, cauliflower-like appearance.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The affected area should be washed thoroughly, and soaking in warm water for approximately 5 minutes may facilitate this process. After washing, the area must be dried completely. A small amount of the medication should then be applied to cover each wart, ensuring that it is allowed to dry. This application should be repeated twice daily as needed, with treatment continuing for a maximum duration of 12 weeks.

Contraindications

Use of this product is contraindicated in the following situations:

Application is not recommended on irritated or infected skin, or in areas exhibiting redness. The product should not be used in patients with diabetes or those who have poor blood circulation, as these conditions may exacerbate potential adverse effects. Additionally, the product is contraindicated for use on birthmarks, warts with hair growth, or moles due to the risk of irritation or other complications.

Warnings and Precautions

For external use only; it is imperative to avoid contact with the eyes. In the event of accidental exposure to the eyes, it is recommended to rinse thoroughly with water for at least 15 minutes. Additionally, users should refrain from inhaling vapors associated with the product.

General precautions should be observed, particularly for individuals who are pregnant or breastfeeding. It is advisable for these individuals to consult a healthcare professional prior to using the product to ensure safety.

In cases of ingestion, immediate medical assistance should be sought, or the local Poison Control Center should be contacted without delay.

Users are advised to discontinue use and consult a physician if discomfort persists, as this may indicate a need for further evaluation or alternative treatment options.

Side Effects

Patients should be aware that the product is intended for external use only. It is crucial to avoid contact with the eyes; in the event of exposure, the affected area should be rinsed with water for 15 minutes. Additionally, patients are advised to avoid inhaling vapors associated with the product.

In the case of persistent discomfort, patients should discontinue use and consult a healthcare professional for further guidance. This recommendation is important to ensure safety and address any potential adverse reactions that may arise during use.

Drug Interactions

No drug interactions have been identified for the product, indicating that it does not exhibit significant pharmacokinetic or pharmacodynamic interactions with other medications. Additionally, there are no known interactions with laboratory tests associated with this product. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Wellreme Wart Removal (salicylic acid 17% wart removal). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or contact with a Poison Control Center is recommended.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. It is essential to evaluate the potential risks and benefits associated with the use of this drug during pregnancy and lactation. Healthcare providers should consider the available data and individual patient circumstances when advising on the use of this medication in these populations.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data on the excretion of this drug in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no dosage adjustments, special monitoring requirements, or precautions recommended for individuals with compromised liver function. It is advised that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be considered based on clinical judgment.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise, as the clinical presentation can vary depending on the substance involved and the individual patient's response. Common symptoms of overdose may include, but are not limited to, altered mental status, cardiovascular instability, respiratory distress, and gastrointestinal disturbances.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should initiate supportive care, which may include maintaining airway patency, providing supplemental oxygen, and ensuring adequate circulation. The use of activated charcoal may be considered if the patient presents within a suitable timeframe and if the ingestion was recent.

Furthermore, specific antidotes or treatments may be indicated based on the substance involved in the overdose. Consultation with a poison control center or a medical toxicologist is recommended to guide the management of the patient and to determine the most appropriate interventions.

Overall, vigilance and prompt action are crucial in managing cases of suspected overdose, even in the absence of detailed information regarding specific overdosage scenarios.

Nonclinical Toxicology

No information is available regarding teratogenic or non-teratogenic effects. Additionally, there is no data provided concerning nonclinical toxicology, animal pharmacology, or toxicology.

Postmarketing Experience

No postmarketing experience details are provided in the insert.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical help or contact a Poison Control Center if the product is swallowed.

Patients should be informed that the product should not be applied to irritated or infected skin, or to reddened areas. Special caution is warranted for individuals who are diabetic or have poor blood circulation, as well as for those considering use on birthmarks, warts with hair growth, or moles.

Healthcare providers should instruct patients to discontinue use and consult a doctor if discomfort persists after application.

Additionally, it is important to recommend that patients who are pregnant or breastfeeding consult a health professional before using the product to ensure safety for both themselves and their child.

Storage and Handling

The product is supplied in a tube format, with specific attention to the integrity of the packaging. It is essential to store the product in a cool, dry place, ensuring it is kept away from light to maintain its efficacy. The container must remain airtight to protect the contents from environmental factors.

Healthcare professionals should be advised not to use the product if the seal on the tube is broken or not visible, as this may compromise the safety and effectiveness of the product.

Additional Clinical Information

The product is administered topically, with a recommended application of a small amount to cover each wart, allowing it to dry. This process may be repeated twice daily as needed, for a duration of up to 12 weeks.

Clinicians should advise patients who are pregnant or breastfeeding to consult a health professional prior to use. Additionally, patients are instructed to discontinue use and seek medical advice if discomfort persists. No further information is available regarding laboratory tests, abuse potential, or postmarketing experiences.

Drug Information (PDF)

This file contains official product information for Wellreme Wart Removal, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)